CliffBio
small molecule

TAVALISSE

FOSTAMATINIB DISODIUM

Loss of exclusivityJuly 2032latest FDA-listed patent expiry
CompanyRigel Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameTAVALISSE
Active ingredientFOSTAMATINIB DISODIUM
StrengthEQ 150MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2018
Marketing statusRX

Listed patents

PatentExpiresType
8771648July 2032product
8951504July 2032use U-2294
7449458September 2031substance
8263122November 2030product
8652492November 2028product
9283238June 2026use U-2294
8163902June 2026substance
8912170June 2026use U-2294
8445485June 2026product
7989448June 2026substance
7538108March 2026substance
8211889January 2026substance
RE48898January 2026product
9266912January 2026use U-2294

More from Rigel Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TAVALISSE patent cliff — loss of exclusivity July 2032 | CliffBio